Yonsei Medical Journal

Yonsei Univ College Medicine (연세대학교의과대학)
권호 표지
DOI QR코드

DOI QR Code

Managing Thyroid Microcarcinomas

  • Mazzaferri, Ernest L. (Division of Endocrinology, Shands Hospital, University of Florida)
  • Published : 2012.02.01
⟨ Previous Next ⟩

Abstract

Papillary thyroid microcarcinomas (PTMCs) are the most common form of classic papillary thyroid carcinoma (PTC). PTMCs are typically discovered by fine-needle-aspiration biopsy (FNAB), usually with sensitive imaging studies, or are found during thyroid surgery in a patient without a previously known history of thyroid carcinoma. However, the definition of PTMC has not always been universally accepted, thus creating controversy concerning the diagnosis and treatment of PTMC. The aim of this review is to summarize the clinical features of PTMC and identify the widely differing opinions concerning the diagnosis and management of these small ubiquitous thyroid tumors.

Keywords

References

  1. DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004. p.54-5.
  2. Greene FL, Sobin LH. The TNM system: our language for cancer care. J Surg Oncol 2002;80:119-20. https://doi.org/10.1002/jso.10114
  3. Schonberger J, Marienhagen J, Agha A, Rozeboom S, Bachmeier E, Schlitt H, et al. Papillary microcarcinoma and papillary cancer of the thyroid
  4. Ries LAG, Harkins D, Krapcho D, Mariotto M, Miller BA, Feurer EJ, et al. SEER Cancer Statistics Review, 1997-2003. http://seer.cancer.gov/csr/1975_2001/results_merged/sect_25_thyroid.pdf [serial online] 2010;SEER Cancer Stat Fact Sheets.
  5. Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid 2011;21:231-6. https://doi.org/10.1089/thy.2010.0137
  6. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 2009;20:525-31. https://doi.org/10.1007/s10552-008-9260-4
  7. Hogan AR, Zhuge Y, Perez EA, Koniaris LG, Lew JI, Sola JE. Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Res 2009;156:167-72. https://doi.org/10.1016/j.jss.2009.03.098
  8. Alston RD, Geraci M, Eden TO, Moran A, Rowan S, Birch JM. Changes in cancer incidence in teenagers and young adults (ages 13 to 24 years) in England 1979-2003. Cancer 2008;113:2807-15. https://doi.org/10.1002/cncr.23901
  9. Steliarova-Foucher E, Stiller CA, Pukkala E, Lacour B, Plesko I, Parkin DM. Thyroid cancer incidence and survival among European children and adolescents (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42:2150-69. https://doi.org/10.1016/j.ejca.2006.06.001
  10. American Cancer Society. Cancer Facts and Figures 2009. http://www.cancer.org. 1-25-2010.
  11. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997;126:226-31. https://doi.org/10.7326/0003-4819-126-3-199702010-00009
  12. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993;328:1237-43. https://doi.org/10.1056/NEJM199304293281706
  13. Pazaitou-Panayiotou K, Capezzone M, Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid 2007;17:1085-92. https://doi.org/10.1089/thy.2007.0005
  14. Baloch ZW, LiVolsi VA. Microcarcinoma of the thyroid. Adv Anat Pathol 2006;13:69-75. https://doi.org/10.1097/01.pap.0000213006.10362.17
  15. Yeo PP, Wang KW, Sinniah R, Aw TC, Chang CH, Sethi VK, et al. Thyrotoxicosis and thyroid cancer. Aust N Z J Med 1982;12: 589-93. https://doi.org/10.1111/j.1445-5994.1982.tb02643.x
  16. Pelizzo MR, Piotto A, Rubello D, Casara D, Fassina A, Busnardo B. High prevalence of occult papillary thyroid carcinoma in a surgical series for benign thyroid disease. Tumori 1990;76:255-7.
  17. Pezzolla A, Lattarulo S, Milella M, Barile G, Pascazio B, Ciampolillo A, et al. [Incidental carcinoma in thyroid pathology: our experience and review of the literature]. Ann Ital Chir 2010;81:165-9.
  18. Yeo PP, Wang KW, Aw TC, Tan EC, Rauff A, Foong WC, et al. Hyperthyroidism with coexisting thyroid carcinoma: a study of 14 patients. Ann Acad Med Singapore 1981;10:323-5.
  19. Belfiore A, La Rosa GL, La Porta GA, Giuffrida D, Milazzo G, Lupo L, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med 1992;93:363-9. https://doi.org/10.1016/0002-9343(92)90164-7
  20. Silliphant WM, Klinck GH, Levitin MS. Thyroid carcinoma and death. A clinicopathological study of 193 autopsies. Cancer 1964; 17:513-25. https://doi.org/10.1002/1097-0142(196404)17:4<513::AID-CNCR2820170413>3.0.CO;2-2
  21. Mortensen JD, Woolner LB, Bennett WA. Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab 1955;15:1270-80. https://doi.org/10.1210/jcem-15-10-1270
  22. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7. https://doi.org/10.1001/jama.295.18.2164
  23. Vanderlaan WP. The occurrence of carcinoma of the thyroid gland in autopsy material. N Engl J Med 1947;237:221. https://doi.org/10.1056/NEJM194708142370703
  24. Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ 2007;177:1357-61. https://doi.org/10.1503/cmaj.061730
  25. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009;18:784-91. https://doi.org/10.1158/1055-9965.EPI-08-0960
  26. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009; 115: 3801-7. https://doi.org/10.1002/cncr.24416
  27. Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003;13:381-7. https://doi.org/10.1089/105072503321669875
  28. Ito Y, Miyauchi A. A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid. Nat Clin Pract Endocrinol Metab 2007;3:240-8. https://doi.org/10.1038/ncpendmet0428
  29. Noguchi S, Yamashita H, Uchino S, Watanabe S. Papillary microcarcinoma. World J Surg 2008;32:747-53. https://doi.org/10.1007/s00268-007-9453-0
  30. Cohen MS, Arslan N, Dehdashti F, Doherty GM, Lairmore TC, Brunt LM, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001;130:941-6. https://doi.org/10.1067/msy.2001.118265
  31. Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 2003;237:399-407.
  32. Roti E, degli Uberti EC, Bondanelli M, Braverman LE. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol 2008;159:659-73. https://doi.org/10.1530/EJE-07-0896
  33. Shie P, Cardarelli R, Sprawls K, Fulda KG, Taur A. Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2009;30:742-8. https://doi.org/10.1097/MNM.0b013e32832ee09d
  34. Mitchell J, Parangi S. The thyroid incidentaloma: an increasingly frequent consequence of radiologic imaging. Semin Ultrasound CT MR 2005;26:37-46. https://doi.org/10.1053/j.sult.2004.10.004
  35. Rossi R, Roti E, Trasforini G, Pansini G, Cavazzini L, Zatelli MC, et al. Differentiated thyroid cancers 11-20 mm in diameter have clinical and histopathologic characteristics suggesting higher aggressiveness than those < or =10 mm. Thyroid 2008;18:309-15. https://doi.org/10.1089/thy.2007.0100
  36. Nam-Goong IS, Kim HY, Gong G, Lee HK, Hong SJ, Kim WB, et al. Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) 2004;60:21-8. https://doi.org/10.1046/j.1365-2265.2003.01912.x
  37. Topliss D. Thyroid incidentaloma: the ignorant in pursuit of the impalpable. Clin Endocrinol (Oxf) 2004;60:18-20. https://doi.org/10.1111/j.1365-2265.2004.01956.x
  38. Leenhardt L, Hejblum G, Franc B, Fediaevsky LD, Delbot T, Le Guillouzic D, et al. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab 1999;84:24-8. https://doi.org/10.1210/jcem.84.1.5418
  39. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002;87:1941-6. https://doi.org/10.1210/jcem.87.5.8504
  40. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007;246:375-81. https://doi.org/10.1097/SLA.0b013e31814697d9
  41. Lin JD, Kuo SF, Chao TC, Hsueh C. Incidental and nonincidental papillary thyroid microcarcinoma. Ann Surg Oncol 2008;15:2287-92. https://doi.org/10.1245/s10434-008-9958-2
  42. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab 2004;89:3713-20. https://doi.org/10.1210/jc.2003-031982
  43. Durante C, Attard M, Torlontano M, Ronga G, Monzani F, Costante G, et al. Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. J Clin Endocrinol Metab 2010;95:4882-8. https://doi.org/10.1210/jc.2010-0762
  44. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998;83:553-9. https://doi.org/10.1002/(SICI)1097-0142(19980801)83:3<553::AID-CNCR25>3.0.CO;2-U
  45. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985;55:794-804. https://doi.org/10.1002/1097-0142(19850215)55:4<794::AID-CNCR2820550418>3.0.CO;2-Z
  46. Page C, Biet A, Boute P, Cuvelier P, Strunski V. 'Aggressive papillary' thyroid microcarcinoma. Eur Arch Otorhinolaryngol 2009; 266:1959-63. https://doi.org/10.1007/s00405-009-0952-5
  47. Falvo L, D'Ercole C, Sorrenti S, D'Andrea V, Catania A, Berni A, et al. Papillary microcarcinoma of the thyroid gland: analysis of prognostic factors including histological subtype. Eur J Surg Suppl 2003:28-32.
  48. Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 2010; 95:4197-205. https://doi.org/10.1210/jc.2010-0337
  49. Autelitano F, Spagnoli LG, Santeusanio G, Villaschi S, Autelitano M. [Occult carcinoma of the thyroid gland: an epidemiological study of autopsy material]. Ann Ital Chir 1990;61:141-6.
  50. Bondeson L, Ljungberg O. Occult thyroid carcinoma at autopsy in Malmö, Sweden. Cancer 1981;47:319-23. https://doi.org/10.1002/1097-0142(19810115)47:2<319::AID-CNCR2820470218>3.0.CO;2-A
  51. Furmanchuk AW, Roussak N, Ruchti C. Occult thyroid carcinomas in the region of Minsk, Belarus. An autopsy study of 215 patients. Histopathology 1993;23:319-25. https://doi.org/10.1111/j.1365-2559.1993.tb01214.x
  52. Otino A, Pianzola HM, Castelletto RH. Occult papillary thyroid carcinoma at autopsy in La Plata, Argentina. Cancer 1989;64:547-51. https://doi.org/10.1002/1097-0142(19890715)64:2<547::AID-CNCR2820640232>3.0.CO;2-N
  53. Sampson RJ, Woolner LB, Bahn RC, Kurland LT. Occult thyroid carcinoma in Olmsted County, Minnesota: prevalence at autopsy compared with that in Hiroshima and Nagasaki, Japan. Cancer 1974;34:2072-6. https://doi.org/10.1002/1097-0142(197412)34:6<2072::AID-CNCR2820340629>3.0.CO;2-#
  54. Fukunaga FH, Lockett LJ. Thyroid carcinoma in the Japanese in Hawaii. Arch Pathol 1971;92:6-13.
  55. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007;110:38-46. https://doi.org/10.1002/cncr.22754
  56. Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 2009;16:240-5. https://doi.org/10.1245/s10434-008-0233-3
  57. Park YJ, Kim YA, Lee YJ, Kim SH, Park SY, Kim KW, et al. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings. Head Neck 2010;32:38-45.
  58. Appetecchia M, Scarcello G, Pucci E, Procaccini A. Outcome after treatment of papillary thyroid microcarcinoma. J Exp Clin Cancer Res 2002;21:159-64.
  59. Barbaro D, Simi U, Meucci G, Lapi P, Orsini P, Pasquini C. Thyroid papillary cancers: microcarcinoma and carcinoma, incidental cancers and non-incidental cancers - are they different diseases? Clin Endocrinol (Oxf) 2005;63:577-81. https://doi.org/10.1111/j.1365-2265.2005.02386.x
  60. Silver RJ, Parangi S. Management of thyroid incidentalomas. Surg Clin North Am 2004;84:907-19. https://doi.org/10.1016/j.suc.2004.02.002
  61. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:4085-90. https://doi.org/10.1210/jc.2007-1179
  62. Pelizzo MR, Boschin IM, Toniato A, Pagetta C, Piotto A, Bernante P, et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun 2004;25:547-52. https://doi.org/10.1097/01.mnm.0000126625.17166.36
  63. Antonaci A, Anello A, Aucello A, Consorti F, Della Rocca C, Giovannone G, et al. Microcarcinoma and incidental carcinoma of the thyroid in a clinical series: clinical behaviour and surgical management. Clin Ter 2006;157:225-9.
  64. Arem R, Padayatty SJ, Saliby AH, Sherman SI. Thyroid microcarcinoma: prevalence, prognosis, and management. Endocr Pract 1999;5:148-56. https://doi.org/10.4158/EP.5.3.148
  65. Lin JD, Chao TC, Hsueh C, Kuo SF. High recurrent rate of multicentric papillary thyroid carcinoma. Ann Surg Oncol 2009;16: 2609-16. https://doi.org/10.1245/s10434-009-0565-7
  66. Lin JD. Increased incidence of papillary thyroid microcarcinoma with decreased tumor size of thyroid cancer. Med Oncol 2010; 27:510-8. https://doi.org/10.1007/s12032-009-9242-8
  67. Solares CA, Penalonzo MA, Xu M, Orellana E. Occult papillary thyroid carcinoma in postmortem species: prevalence at autopsy. Am J Otolaryngol 2005;26:87-90. https://doi.org/10.1016/j.amjoto.2004.08.003
  68. Lang W, Borrusch H, Bauer L. Occult carcinomas of the thyroid. Evaluation of 1,020 sequential autopsies. Am J Clin Pathol 1988; 90:72-6. https://doi.org/10.1093/ajcp/90.1.72
  69. Sobrinho-Simoes MA, Sambade MC, Goncalves V. Latent thyroid carcinoma at autopsy: a study from Oporto, Portugal. Cancer 1979;43:1702-6. https://doi.org/10.1002/1097-0142(197905)43:5<1702::AID-CNCR2820430521>3.0.CO;2-S
  70. King DL, Stack BC Jr, Spring PM, Walker R, Bodenner DL. Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas. Otolaryngol Head Neck Surg 2007;137:400-4. https://doi.org/10.1016/j.otohns.2007.02.037
  71. Zhai G, Zhang M, Xu H, Zhu C, Li B. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography whole body imaging in the evaluation of focal thyroid incidentaloma. J Endocrinol Invest 2010;33:151-5. https://doi.org/10.1007/BF03346574
  72. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404. https://doi.org/10.1210/jc.2003-030838
  73. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004;45:818-21. https://doi.org/10.3349/ymj.2004.45.5.818
  74. Giannini R, Ugolini C, Lupi C, Proietti A, Elisei R, Salvatore G, et al. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:3511-6. https://doi.org/10.1210/jc.2007-0594
  75. Brierre JT Jr, Dickson LG. Clinically unsuspected thyroid disease. GP 1964;30:94-8.
  76. Komorowski RA, Hanson GA. Occult thyroid pathology in the young adult: an autopsy study of 138 patients without clinical thyroid disease. Hum Pathol 1988;19:689-96. https://doi.org/10.1016/S0046-8177(88)80175-8

Cited by

  1. Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors vol.2013, pp.None, 2013, https://doi.org/10.1155/2013/965212
  2. Preoperative Prediction of Central Lymph Node Metastasis in Thyroid Papillary Microcarcinoma Using Clinicopathologic and Sonographic Features vol.37, pp.2, 2012, https://doi.org/10.1007/s00268-012-1826-3
  3. BRAF(V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma : BRAFMutation in Micro-PTC on vol.121, pp.6, 2012, https://doi.org/10.1002/cncy.21258
  4. Papillary Thyroid Microcarcinoma : How to Diagnose and Manage this Epidemic? vol.22, pp.2, 2014, https://doi.org/10.1177/1066896913517394
  5. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review vol.21, pp.6, 2014, https://doi.org/10.1530/erc-14-0286
  6. Papillary Thyroid Microcarcinomas Are Different from Latent Papillary Thyroid Carcinomas at Autopsy vol.29, pp.5, 2014, https://doi.org/10.3346/jkms.2014.29.5.676
  7. Characteristics and Survival of Breast Cancer Patients with Multiple Synchronous or Metachronous Primary Cancers vol.56, pp.5, 2012, https://doi.org/10.3349/ymj.2015.56.5.1213
  8. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma vol.173, pp.4, 2012, https://doi.org/10.1530/eje-15-0254
  9. Association between p16 Promoter Methylation and Thyroid Cancer Risk: A Meta-analysis vol.16, pp.16, 2012, https://doi.org/10.7314/apjcp.2015.16.16.7111
  10. Epidemiological trends of hormone-related cancers in Slovenia vol.67, pp.2, 2012, https://doi.org/10.1515/aiht-2016-67-2731
  11. Detection of Tumor Multifocality Is Important for Prediction of Tumor Recurrence in Papillary Thyroid Microcarcinoma: A Retrospective Study and Meta-Analysis vol.50, pp.4, 2012, https://doi.org/10.4132/jptm.2016.03.29
  12. Alcohol Intake and Risk of Thyroid Cancer: A Meta-Analysis of Observational Studies vol.49, pp.2, 2012, https://doi.org/10.4143/crt.2016.161
  13. Too Much of a Good Thing: Radioactive Iodine Ablation Use for Micropapillary Thyroid Carcinoma vol.84, pp.5, 2012, https://doi.org/10.1177/000313481808400513
  14. Comparative study on operative trauma between microwave ablation and surgical treatment for papillary thyroid microcarcinoma vol.6, pp.15, 2012, https://doi.org/10.12998/wjcc.v6.i15.936
  15. Fine-needle aspiration cytology of nodular thyroid lesions: A 1-year experience of the thyroid cytopathology in a large regional and a University Hospital, with histological correlation vol.16, pp.2, 2012, https://doi.org/10.4103/trp.trp_34_18
  16. Analysis of Malignant Thyroid Nodules That Do Not Meet ACR TI-RADS Criteria for Fine-Needle Aspiration vol.216, pp.2, 2012, https://doi.org/10.2214/ajr.20.23123